NEXT Oncology enrolls first patient in Madrid phase I clinical research center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NEXT Oncology – Madrid enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer with an anti-drug conjugate used in monotherapy or in combination with antiPDL1. NEXT Oncology expanded to Spain in late 2021.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. 

Login